4P-Pharma Welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as Independent Members of Its Board
Marina Vasiliou, Biogen France President and Managing Director Christian Bechon, Senior Partner chez Isalys Augmented Management Alain Sainsot, GTP Bioways founder and President
4P-Pharma, a clinical-stage startup based in Lille that develops disease-modifying therapies for untreated serious diseases, is delighted to welcome Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent and non-executive members to its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909483462/en/
4P-Pharma welcomes Marina Vasiliou, Christian Bechon and Alain Sainsot as independent members of its board (Photo: Business Wire)
These novel additions will strengthen 4P-Pharma's goal to become a commercial-stage, fully integrated biopharma company covering the whole value chain from discovery to commercialization.
Revital Rattenbach, CEO of 4P-Pharma, says: "We proudly welcome three exceptional leaders to our Board of Directors. Each new member brings substantial expertise and proven leadership abilities, which are crucial to 4P-Pharma during this period of significant company growth."
Concerning the new members:
- Marina Vasiliou, Biogen France President and Managing Director
Marina Vasiliou has been serving as the President and Managing Director of Biogen France since 2021. Biogen is a pioneering international biotechnology company at the forefront of science and innovation, developing tomorrow's medicines in neurology, neuropsychiatry, immunology, and rare diseases. Marina Vasiliou's insights are essential in navigating regulatory requirements and market access strategies. She has experience managing commercial launches and reimbursement in different international settings, including the US, mainly in chronic and rare disease therapies.
"Contributing with my global commercial leadership expertise to supporting 4P-Pharma ambition fills me with great satisfaction. I fully believe in the company's mission to enhance patients' access to first-in-class therapies for untreated serious diseases. I trust the commitment and innovation of 4P-Pharma's CEO and executive team, and I am thrilled to work with them on a diverse Board of Directors," declared Marina Vasiliou.
- Christian Bechon, Senior Partner chez Isalys Augmented Management
Christian Bechon is the former Chairman and CEO of LFB Group. Under his leadership, LFB Group has transformed from a French leader in plasma cell fractionation to an internationally recognized player with a global footprint.
"4P-Pharma is a promising French biotech company that prioritizes patients' needs. The company's main objective is to contribute to healthcare innovation in France and Europe while maintaining its independence. I am privileged to be a part of this entrepreneurial journey and provide valuable guidance to the leadership team to catalyze 4P-Pharma’s next wave of growth," said Christian Bechon.
- Alain Sainsot, GTP Bioways founder and President
Alain Sainsot, Founder and President of GTP Bioways, has served as Senior Director of Group Operations and Logistics for leading pharmaceutical companies like Pierre Fabre. He is a serial industrial entrepreneur who created two fast-growing CDMOs, Amatsi-group (acquired) and GTP-Bioways. He brings extensive experience in the industrial anchor of drug development to 4P-Pharma.
"It is an honor for me to join 4P-Pharma in their mission to develop innovative drugs for patients. I am confident in Revital Rattenbach's dedication and her leadership team's commitment to providing first-in-class treatments to patients. I look forward to joining forces and implementing the highest quality standards to industrialize 4P-Pharma's promising therapeutic pipeline further," stated Alain Sainsot.
Concerning the Board of Directors of 4P-Pharma
These new members reinforce the existing 4P-Pharma Board of Directors, which is composed of robust and well-known life science experts.
Their comprehensive industry knowledge and extensive network strengthen the company's credibility and strategic vision in the biotech and pharma sectors.
Jean Pierre Lehner,Chairman of the 4P-Pharma Board of Directors, concluded: "I am thrilled by Marina Vasiliou, Christian Bechon, and Alain Sainsot's enthusiasm for joining our Board. Their combined expertise will accelerate our mission and strengthen our ability to bring innovative therapies to those in need."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909483462/en/
Contacts
Press Contact
Press Contact
Communication – media Relations
Emmanuel Dadjé - Communication Manager
Emmanuel.dadje@4P-Pharma.com
Tel : +33 6 30 06 12 13
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting17.12.2025 13:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Board), will comprise the Board of the Company until the trial listed in late April/early May 2026. The Antigua High Court decision arises from a hearing that took place on 27 October 2025, at which applicants SAIF Partners IV L.P., OrbiMed Partners Master Fund Limited and 1Globe Capital LLC each sought injunctions to confirm the composition of their respective favoured Boards, pending determination of a dispute over the outcome of the Company’s Special Shareholders Meeting on 8 July 2025 (the SSM Dispute). The hearing of the SSM Dispute has been scheduled to take place in the Antigua High Court in late April/early May 2026, with judgment to be de
Akamai and Visa Collaborate to Build Trust in Agentic Commerce17.12.2025 13:00:00 CET | Press release
Visa’s Trusted Agent Protocol to authenticate AI shopping agents and help prevent fraud across Akamai Cloud, strengthening the trust layer in agentic commerce Akamai Technologies, Inc. (NASDAQ: AKAM), the cybersecurity and cloud computing company that powers and protects business online, today announced a strategic collaboration with Visa (NYSE: V) to bring stronger identity, user recognition, and security controls to the emerging world of agentic commerce. Through its integration of Visa’s Trusted Agent Protocol with Akamai’s edge-based behavioral intelligence, user recognition, and bot and abuse protection, the companies will deliver the identity, authentication, and fraud controls required to let merchants confidently welcome AI agents with commerce intent into their digital storefronts. As autonomous AI agents increasingly browse, compare, and purchase on behalf of consumers, merchants face a new array of challenges. Merchants must now be able to differentiate this new type of legi
Mercans Launches the World’s First AI-Powered Globally Intelligent Workforce & Leave Management Engine17.12.2025 11:50:00 CET | Press release
A Unified Platform That Converts Unevaluated Time Data into Country- and Client-Compliant Workforce Transactions in Real Time Mercans, a global leader in payroll technology, workforce management, and HR SaaS solutions, today announced the launch of its next-generation Workforce Management (WFM) and Leave Management Engine - the world’s first platform capable of evaluating unevaluated time and attendance data against any country-specific legislation and client-specific policy framework, and converting it into fully evaluated, payroll-ready time transactions. This breakthrough engine fundamentally transforms how organizations manage time, attendance, and leave across borders by eliminating manual rule interpretation, fragmented systems, and country-by-country customizations. Solving a Global Workforce Challenge Traditional time and attendance systems capture raw or unevaluated data - clock-ins, clock-outs, absences, and leave requests - but fail to interpret that data in context. The res
EIG’s MidOcean Energy Completes Acquisition of Interest in Canada from PETRONAS17.12.2025 09:58:00 CET | Press release
MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the completion of its acquisition of a 20% interest in PETRONAS’ key entities in Canada. The transaction includes a 20% interest in the North Montney Upstream Joint Venture (“NMJV”), which holds PETRONAS’ upstream investment in Canada, and a 20% interest in the North Montney LNG Limited Partnership (“NMLLP”), which holds PETRONAS’ 25% participating interest in the LNG Canada Project. This strategic investment positions MidOcean across the LNG value chain, securing upstream resources and downstream liquefaction through the LNG Canada Project, with around 0.7 MTPA of associated LNG and potential to grow further. RBC Capital Markets acted as financial advisor to MidOcean, and Latham & Watkins acted as legal advisor. About EIG EIG is a leading institutional investor in the global energy and infrastru
Nexo Announces Landmark Crypto Partnership with Tennis Australia for Australian Open and Summer of Tennis17.12.2025 09:00:00 CET | Press release
Nexo has signed a landmark multi-year deal with Tennis Australia, covering the Australian Open and the Summer of Tennis. The partnership delivers exclusive experiences, including a feature in the Coachеs Pod. The announcement continues Nexo’s rapid global expansion, following three other major sports partnerships in 2025. Nexo, the premier digital assets platform, has entered a landmark multi-year global partnership with Tennis Australia, becoming the Official Crypto Partner of the Australian Open and the Summer of Tennis, including the United Cup, Adelaide International, Brisbane International, and Hobart International. This agreement marks the first time a digital asset company has partnered with a Grand Slam tournament, affirming Nexo’s prestige, long-term vision, and leadership at the intersection of elite sport and digital assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216497915/en/ Antoni Trenchev, Co-founde
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom